236 related articles for article (PubMed ID: 35274474)
41. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity.
Loos C; Atyeo C; Fischinger S; Burke J; Slein MD; Streeck H; Lauffenburger D; Ryan ET; Charles RC; Alter G
mSphere; 2020 Sep; 5(5):. PubMed ID: 32878931
[TBL] [Abstract][Full Text] [Related]
42. Emerging Technologies for the Treatment of COVID-19.
Aghamollaei H; Sarvestani R; Bakherad H; Zare H; Guest PC; Ranjbar R; Sahebkar A
Adv Exp Med Biol; 2021; 1321():81-96. PubMed ID: 33656715
[TBL] [Abstract][Full Text] [Related]
43. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2.
Bowden-Reid E; Ledger S; Zhang Y; Di Giallonardo F; Aggarwal A; Stella AO; Akerman A; Milogiannakis V; Walker G; Rawlinson W; Turville S; Kelleher AD; Ahlenstiel C
Antiviral Res; 2023 Sep; 217():105677. PubMed ID: 37478918
[TBL] [Abstract][Full Text] [Related]
44. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
45. Etiology and clinical characteristics of SARS-CoV-2 and other human coronaviruses among children in Zhejiang Province, China 2017-2019.
Zhang Y; Su L; Chen Y; Yu S; Zhang D; Mao H; Fang L
Virol J; 2021 Apr; 18(1):89. PubMed ID: 33931105
[TBL] [Abstract][Full Text] [Related]
46. Coronavirus - A Crippling Affliction to Humans.
Kaul R; Devi S
Recent Pat Biotechnol; 2022 Aug; 16(3):226-242. PubMed ID: 35379131
[TBL] [Abstract][Full Text] [Related]
47. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.
Clemente V; D'Arcy P; Bazzaro M
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429099
[TBL] [Abstract][Full Text] [Related]
48. Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era.
Dzuvor CKO; Tettey EL; Danquah MK
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 May; 14(3):e1785. PubMed ID: 35238490
[TBL] [Abstract][Full Text] [Related]
49. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
Krishna G; Pillai VS; Veettil MV
Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
[TBL] [Abstract][Full Text] [Related]
50. Lipid-based therapies against SARS-CoV-2 infection.
Alketbi EH; Hamdy R; El-Kabalawy A; Juric V; Pignitter M; A Mosa K; Almehdi AM; El-Keblawy AA; Soliman SSM
Rev Med Virol; 2021 Sep; 31(5):1-13. PubMed ID: 34546604
[TBL] [Abstract][Full Text] [Related]
51. From SARS coronavirus to novel animal and human coronaviruses.
To KK; Hung IF; Chan JF; Yuen KY
J Thorac Dis; 2013 Aug; 5 Suppl 2(Suppl 2):S103-8. PubMed ID: 23977429
[TBL] [Abstract][Full Text] [Related]
52. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.
Abd El-Aziz TM; Stockand JD
Infect Genet Evol; 2020 Sep; 83():104327. PubMed ID: 32320825
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of SARS-CoV-2 Replication by a Small Interfering RNA Targeting the Leader Sequence.
Tolksdorf B; Nie C; Niemeyer D; Röhrs V; Berg J; Lauster D; Adler JM; Haag R; Trimpert J; Kaufer B; Drosten C; Kurreck J
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696460
[TBL] [Abstract][Full Text] [Related]
54. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
[TBL] [Abstract][Full Text] [Related]
55. DNA aptamers masking angiotensin converting enzyme 2 as an innovative way to treat SARS-CoV-2 pandemic.
Villa A; Brunialti E; Dellavedova J; Meda C; Rebecchi M; Conti M; Donnici L; De Francesco R; Reggiani A; Lionetti V; Ciana P
Pharmacol Res; 2022 Jan; 175():105982. PubMed ID: 34798263
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
[TBL] [Abstract][Full Text] [Related]
57. Molecular biology of coronaviruses: an overview of virus-host interactions and pathogenesis.
Hidalgo P; Valdés M; González RA
Bol Med Hosp Infant Mex; 2021; 78(1):41-58. PubMed ID: 33661875
[TBL] [Abstract][Full Text] [Related]
58. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
Zhuang MW; Cheng Y; Zhang J; Jiang XM; Wang L; Deng J; Wang PH
J Med Virol; 2020 Nov; 92(11):2693-2701. PubMed ID: 32497323
[TBL] [Abstract][Full Text] [Related]
59. Molecular targeting of vulnerable RNA sequences in SARS CoV-2: identifying clinical feasibility.
Gallicano GI; Casey JL; Fu J; Mahapatra S
Gene Ther; 2022 May; 29(5):304-311. PubMed ID: 33184504
[TBL] [Abstract][Full Text] [Related]
60. Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism.
Shawon J; Akter Z; Hossen MM; Akter Y; Sayeed A; Junaid M; Afrose SS; Khan MA
Curr Pharm Des; 2020; 26(41):5241-5260. PubMed ID: 33155902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
